225 related articles for article (PubMed ID: 30353166)
1. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
Wagner S; Vlachogiannis G; De Haven Brandon A; Valenti M; Box G; Jenkins L; Mancusi C; Self A; Manodoro F; Assiotis I; Robinson P; Chauhan R; Rust AG; Matthews N; Eason K; Khan K; Starling N; Cunningham D; Sadanandam A; Isacke CM; Kirkin V; Valeri N; Whittaker SR
Oncogene; 2019 Mar; 38(10):1717-1733. PubMed ID: 30353166
[TBL] [Abstract][Full Text] [Related]
2. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
4. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
5. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
[TBL] [Abstract][Full Text] [Related]
6. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
7. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
8. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
9. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
[TBL] [Abstract][Full Text] [Related]
10. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
11. Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells.
Hirashita Y; Tsukamoto Y; Kudo Y; Kakisako D; Kurogi S; Hijiya N; Nakada C; Uchida T; Hirashita T; Hiratsuka T; Akagi T; Ueda Y; Shiroshita H; Etoh T; Mizukami K; Honda K; Okimoto T; Kodama M; Inomata M; Moriyama M; Murakami K
Lab Invest; 2021 Aug; 101(8):1036-1047. PubMed ID: 33911189
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in
Weisner J; Landel I; Reintjes C; Uhlenbrock N; Trajkovic-Arsic M; Dienstbier N; Hardick J; Ladigan S; Lindemann M; Smith S; Quambusch L; Scheinpflug R; Depta L; Gontla R; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Maghnouj A; Müller MP; Pohl M; Teschendorf C; Wolters H; Viebahn R; Tannapfel A; Uhl W; Hengstler JG; Hahn SA; Siveke JT; Rauh D
Cancer Res; 2019 May; 79(9):2367-2378. PubMed ID: 30858154
[TBL] [Abstract][Full Text] [Related]
13. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
15. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
17. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
18. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
[TBL] [Abstract][Full Text] [Related]
19. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.
Carson R; Celtikci B; Fenning C; Javadi A; Crawford N; Carbonell LP; Lawler M; Longley DB; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2015 Jul; 21(14):3230-3240. PubMed ID: 25813020
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]